Neon Therapeutics announced the appointment of Hugh O'Dowd to chief executive officer. Mr. O'Dowd succeeds interim chief executive officer Cary Pfeffer, M.D., a partner at Third Rock Ventures, who is assuming the position of chairman of the company's board of directors. Mr. O'Dowd brings deep experience to the company in pharmaceutical leadership, moving important oncology therapies from clinical development through commercialization.

He joins the company from Novartis.